Energy co. makes $100,000 donation to Houston hospital

curing ALS

Energy Transfer, a Dallas-based midstream energy company, just donated $100,000 to Houston Methodist. Photo via TMC.edu

Where do energy transition and life-saving medicine meet? In Texas, of course.

Energy Transfer, a Dallas-based midstream energy company, just donated $100,000 to Houston Methodist. The grant is part of a $200,000 gift that has spanned the past two years. The goal? To eradicate the neurological disorder, ALS (amyotrophic lateral sclerosis). There is currently no cure for ALS. For roughly 90 percent of patients, there’s no known genetic cause, meaning the disease can strike anyone.

Houston Methodist currently has numerous clinical trials taking place with the goal to slow or halt the progression of the degenerative ailment.

“Every dollar donated to ALS research is a beacon of hope for those battling the disease,” said Chris Curia, executive vice president and chief human resources officer at Energy Transfer. “Those affected by ALS deserve a chance at a better life. We are hopeful this donation brings us one step closer to a world without this disease.”

Houston Methodist is home to the first multidisciplinary care clinic for ALS patients in the region and is actively engaged in both clinical and basic scientific research to support people battling ALS.

“We appreciate Energy Transfer’s generosity in our efforts to improve the quality of life and to provide hope for ALS patients and their families. Their continued commitment to Houston Methodist’s ongoing ALS research is truly transformational,” says Stanley H. Appel, M.D., a pioneering neurologist at Houston Methodist whose lab focuses on neurodegenerative diseases, including ALS.

Energy Transfer’s gift will help to support one particularly promising trial of a combination therapy that is currently moving into Phase 2. In its first phase, the therapy was found to safely slow disease progression in four ALS patients over a six-month period. Those patients had no significant progression of their disease during the trial. Prior to receiving the therapy, each of the patients had reported declining abilities to perform daily tasks.

Energy Transfer’s good deed could mean the world not only to patients at Houston Methodist, but to ending ALS altogether.

------

This article originally ran on EnergyCapital.

From Your Site Articles
Daniel Barvin has a neurodegenerative disease in his near future. He joined Houston-based Coya Therapeutics to help fight for a cure to the aggressively deadly ALS. Photo via Getty Images

How this Houston innovator is using his personal connection to ALS fuel his fight for a cure

guest column

We can never predict how our lives will turn out, but then maybe some of us can. Genetic testing showed that I, like my grandfather, aunt, uncle and father before me, would most likely die of amyotrophic lateral sclerosis, more commonly known as ALS, and/or frontotemporal degeneration (FTD) in my 40s.

Being 36, it’s possible that fear could have overtaken my life, but instead I chose to fight for every chance to change not only my life, but the lives of millions who are suffering or may one day suffer from neurodegenerative disease.

ALS is a rare disease that robs one of their ability to control their muscles, leading them to lose their ability to walk, talk and eventually breathe. Eighty percent of cases are sporadic (of unknown origin) and 20 percent have known genetic causes.

When I learned that I carried the C9ORF72 genetic variant, a causative genetic variant for ALS/FTD) my first instincts were to help others understand their status and where they could turn for help. I saw a vacuum for resources and understanding in the genetic ALS space and I knew that thousands were suffering in darkness.

Through the efforts of many, we created the first ever nonprofit – Genetic ALS & FTD: End the Legacy – focused on fighting for the genetic ALS and FTD communities. After making great strides to fight for our rights and access to care, I was asked if I could help my current CEO, Howard Berman, commercialize Dr. Stanley Appel’s regulatory T Cell (Treg) therapy for ALS.

I joined Coya Therapeutics in 2021 as the first employee, working to build a company that would one day bring life changing therapies to patients. Coya’s therapies are based on Dr. Appel’s discovery that neurodegenerative diseases drive an inflammatory response. As inflammation rises, it damages regulatory T cells, and when Tregs are damaged, inflammation becomes a persistent condition driving degeneration and eventually death.

It was at that point that my life changed from the advocacy world to the therapeutic world. Now over three years later, we are closer than ever to making a paradigm change for how patients with ALS and other neurodegenerative diseases are treated.

At Coya, we believe that combination biologics are the future of treating neurodegenerative diseases. COYA 302 is our lead asset, which has shown promising results in a proof-of-concept study released in March of 2023. We are currently working towards a double-blind, placebo-controlled trial for COYA 302 in ALS set to kick off later this year.

I never wanted to live a life so damned by disease, but when put between a rock and a hard place, the only choice is to fight. I don’t know how my life will end, but I hope that my children will know that I faced a great challenge head on with pride and resilience.

In the end, it is the combination of both the worlds I work in that lead to better outcomes for patients, raising awareness and lifesaving research. This ALS Awareness Month, please join us and our partners like the ALS Association, End the Legacy, and I AM ALS in raising awareness about these conditions, their risks, and treatment options.

------

Daniel Barvin is the vice president of operations and patient advocacy at Coya Therapeutics.

For Howard Berman, CEO and co-founder of Coya Therapeutics, commercializing his company is personal. Photo courtesy of Coya

Why this Houston innovator is racing to commercialize its unique treatment for neurodegenerative diseases

HOUSTON INNOVATORS PODCAST EPISODE 182

When Howard Berman sought out renowned Houston Methodist researcher and neurologist Dr. Stanley Appel, he was looking for treatment for his father, who was suffering from dementia. He wasn't looking for a job, but Dr. Appel had other ideas and asked Berman to meet with him.

"I was interested in what I could do for my dad," Berman says on the Houston Innovators Podcast, explaining how he took the meeting with Dr. Appel, who then presented him with some of his research. "By slide five my jaw had hit the ground.

"He had shown that he could stop the progression in one of his early trials of ALS," Berman says.

Not too long after that meeting, Berman, who founded digital health platform imaware, joined Dr. Appel to lead commercialization of Coya Therapeutics, a biotech startup that raised over $20 million in venture funding before going public a few months ago.

Coya has developed a biologics therapy that prevents further spreading of neurodegenerative diseases by making regulatory T cells functional again. Diseases like ALS, the company's focus right now, prevent T-regs from doing their job in controlling inflammation, and without these cells hard at work, the human body doesn't stand a chance in fighting autoimmune threats.

Berman, as co-founder and CEO, has been at the helm of the company leading it through both the fundraising and IPO processes. Coya's IPO occured in a tough market — only 12 biotech companies went public last year, he explains. To Berman, that just proves how passionate the team was about getting this product to those who need it.

"It really says something for the fortitude and our team to come together to make it happen," he says on the show. "We're able to deliver and execute in a difficult market climate.

"Once you're a public company, you have different expectations," he continues. "But you also have the opportunity to go out and attract additional investors in ways you can't do as a private company."

For Berman, whose father passed away earlier this year, it's a personal motivation that drives him to lead the company — as well as an opportunity to advance the city of Houston.

"The next number of years as we develop this therapeutic regimen for ALS, we have the potential to transform Houston into something more than it is currently," he says. "Our success will be the city's success."

Berman shares more of the Coya Therapeutics story on the podcast, as well as how he sees Houston's potential as an emerging hub for biotech. Listen to the interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston researchers develop material to boost AI speed and cut energy use

ai research

A team of researchers at the University of Houston has developed an innovative thin-film material that they believe will make AI devices faster and more energy efficient.

AI data centers consume massive amounts of electricity and use large cooling systems to operate, adding a strain on overall energy consumption.

“AI has made our energy needs explode,” Alamgir Karim, Dow Chair and Welch Foundation Professor at the William A. Brookshire Department of Chemical and Biomolecular Engineering at UH, explained in a news release. “Many AI data centers employ vast cooling systems that consume large amounts of electricity to keep the thousands of servers with integrated circuit chips running optimally at low temperatures to maintain high data processing speed, have shorter response time and extend chip lifetime.”

In a report recently published in ACS Nano, Karim and a team of researchers introduced a specialized two-dimensional thin film dielectric, or electric insulator. The film, which does not store electricity, could be used to replace traditional, heat-generating components in integrated circuit chips, which are essential hardware powering AI.

The thinner film material aims to reduce the significant energy cost and heat produced by the high-performance computing necessary for AI.

Karim and his former doctoral student, Maninderjeet Singh, used Nobel prize-winning organic framework materials to develop the film. Singh, now a postdoctoral researcher at Columbia University, developed the materials during his doctoral training at UH, along with Devin Shaffer, a UH professor of civil engineering, and doctoral student Erin Schroeder.

Their study shows that dielectrics with high permittivity (high-k) store more electrical energy and dissipate more energy as heat than those with low-k materials. Karim focused on low-k materials made from light elements, like carbon, that would allow chips to run cooler and faster.

The team then created new materials with carbon and other light elements, forming covalently bonded sheetlike films with highly porous crystalline structures using a process known as synthetic interfacial polymerization. Then they studied their electronic properties and applications in devices.

According to the report, the film was suitable for high-voltage, high-power devices while maintaining thermal stability at elevated operating temperatures.

“These next-generation materials are expected to boost the performance of AI and conventional electronics devices significantly,” Singh added in the release.

Houston to become 'global leader in brain health' and more innovation news

Top Topics

Editor's note: The most-read Houston innovation news this month is centered around brain health, from the launch of Project Metis to Rice''s new Amyloid Mechanism and Disease Center. Here are the five most popular InnovationMap stories from December 1-15, 2025:

1. Houston institutions launch Project Metis to position region as global leader in brain health

The Rice Brain Institute, UTMB's Moody Brain Health Institute and Memorial Hermann’s comprehensive neurology care department will lead Project Metis. Photo via Unsplash.

Leaders in Houston's health care and innovation sectors have joined the Center for Houston’s Future to launch an initiative that aims to make the Greater Houston Area "the global leader of brain health." The multi-year Project Metis, named after the Greek goddess of wisdom and deep thought, will be led by the newly formed Rice Brain Institute, The University of Texas Medical Branch's Moody Brain Health Institute and Memorial Hermann’s comprehensive neurology care department. The initiative comes on the heels of Texas voters overwhelmingly approving a ballot measure to launch the $3 billion, state-funded Dementia Prevention and Research Institute of Texas (DPRIT). Continue reading.

2.Rice University researchers unveil new model that could sharpen MRI scans

New findings from a team of Rice University researchers could enhance MRI clarity. Photo via Unsplash.

Researchers at Rice University, in collaboration with Oak Ridge National Laboratory, have developed a new model that could lead to sharper imaging and safer diagnostics using magnetic resonance imaging, or MRI. In a study published in The Journal of Chemical Physics, the team of researchers showed how they used the Fokker-Planck equation to better understand how water molecules respond to contrast agents in a process known as “relaxation.” Continue reading.

3. Rice University launches new center to study roots of Alzheimer’s and Parkinson’s

The new Amyloid Mechanism and Disease Center will serve as the neuroscience branch of Rice’s Brain Institute. Photo via Unsplash.

Rice University has launched its new Amyloid Mechanism and Disease Center, which aims to uncover the molecular origins of Alzheimer’s, Parkinson’s and other amyloid-related diseases. The center will bring together Rice faculty in chemistry, biophysics, cell biology and biochemistry to study how protein aggregates called amyloids form, spread and harm brain cells. It will serve as the neuroscience branch of the Rice Brain Institute, which was also recently established. Continue reading.

4. Baylor center receives $10M NIH grant to continue rare disease research

BCM's Center for Precision Medicine Models has received funding that will allow it to study more complex diseases. Photo via Getty Images

Baylor College of Medicine’s Center for Precision Medicine Models has received a $10 million, five-year grant from the National Institutes of Health that will allow it to continue its work studying rare genetic diseases. The Center for Precision Medicine Models creates customized cell, fly and mouse models that mimic specific genetic variations found in patients, helping scientists to better understand how genetic changes cause disease and explore potential treatments. Continue reading.

5. Luxury transportation startup connects Houston with Austin and San Antonio

Shutto is a new option for Houston commuters. Photo courtesy of Shutto

Houston business and leisure travelers have a luxe new way to hop between Texas cities. Transportation startup Shutto has launched luxury van service connecting San Antonio, Austin, and Houston, offering travelers a comfortable alternative to flying or long-haul rideshare. Continue reading.

Texas falls to bottom of national list for AI-related job openings

jobs report

For all the hoopla over AI in the American workforce, Texas’ share of AI-related job openings falls short of every state except Pennsylvania and Florida.

A study by Unit4, a provider of cloud-based enterprise resource planning (ERP) software for businesses, puts Texas at No. 49 among the states with the highest share of AI-focused jobs. Just 9.39 percent of Texas job postings examined by Unit4 mentioned AI.

Behind Texas are No. 49 Pennsylvania (9.24 percent of jobs related to AI) and No. 50 Florida (9.04 percent). One spot ahead of Texas, at No. 47, is California (9.56 percent).

Unit4 notes that Texas’ and Florida’s low rankings show “AI hiring concentration isn’t necessarily tied to population size or GDP.”

“For years, California, Texas, and New York dominated tech hiring, but that’s changing fast. High living costs, remote work culture, and the democratization of AI tools mean smaller states can now compete,” Unit4 spokesperson Mark Baars said in a release.

The No. 1 state is Wyoming, where 20.38 percent of job openings were related to AI. The Cowboy State was followed by Vermont at No. 2 (20.34 percent) and Rhode Island at No. 3 (19.74 percent).

“A company in Wyoming can hire an AI engineer from anywhere, and startups in Vermont can build powerful AI systems without being based in Silicon Valley,” Baars added.

The study analyzed LinkedIn job postings across all 50 states to determine which ones were leading in AI employment. Unit4 came up with percentages by dividing the total number of job postings in a state by the total number of AI-related job postings.

Experts suggest that while states like Texas, California and Florida “have a vast number of total job postings, the sheer volume of non-AI jobs dilutes their AI concentration ratio,” according to Unit4. “Moreover, many major tech firms headquartered in California are outsourcing AI roles to smaller, more affordable markets, creating a redistribution of AI employment opportunities.”

View All Listings